Abstract
Pegylated liposomal doxorubicin (PLD) is a drug whose use is increasingly common. It has been associated with a lower rate of haematologic and cardiac side effects than its nonencapsulated form. However, mucocutaneous toxicity is quite frequent and can be severe. Here we provide a case report of a patient who developed an intertrigolike eruption during treatment with PLD.
MeSH terms
-
Adult
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / etiology
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / analogs & derivatives*
-
Drug Eruptions / pathology*
-
Female
-
Humans
-
Intertrigo / chemically induced*
-
Intertrigo / pathology*
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local
-
Neoplasm Staging
-
Polyethylene Glycols / administration & dosage
-
Polyethylene Glycols / adverse effects*
Substances
-
Antibiotics, Antineoplastic
-
liposomal doxorubicin
-
Polyethylene Glycols
-
Doxorubicin